Endothelial dysfunction and lung capillary injury in cardiovascular diseases by Guazzi M. et al.
  	

Endothelial Dysfunction and Lung Capillary Injury in Cardiovascular Diseases
Marco Guazzi, Shane A. Philips, Ross Arena, Carl J. Lavie
PII: S0033-0620(14)00171-6
DOI: doi: 10.1016/j.pcad.2014.11.003
Reference: YPCAD 632
To appear in: Progress in Cardiovascular Diseases
Please cite this article as: Guazzi Marco, Philips Shane A., Arena Ross, Lavie Carl J.,
Endothelial Dysfunction and Lung Capillary Injury in Cardiovascular Diseases, Progress
in Cardiovascular Diseases (2014), doi: 10.1016/j.pcad.2014.11.003
This is a PDF file of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that
apply to the journal pertain.
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Endothelial Dysfunction and Lung Capillary Injury in Cardiovascular Diseases 
 
 
 
Marco Guazzi, MD, PhD, FACC1, Shane A. Philips, PhD, PT2, Ross Arena, PhD, PT2, Carl J. Lavie, MD3 
 
1Cardiology, I.R.C.C.S. Policlinico San Donato, University of Milano, San Donato Milanese, Italy. 
 
2Department of Physical Therapy and Integrative Physiology Laboratory, College of Applied Health Sciences, 
University of Illinois, Chicago, IL. 
 
3Department of Cardiovascular Diseases, John Ochsner Heart and Vascular Institute, Ochsner Clinical 
School-The University of Queensland School of Medicine, New Orleans, USA. 
 
 
 
 
 
Address for correspondence: 
Marco Guazzi, MD, PhD, FACC 
Associate Professor of Cardiology University of Milano 
Heart Failure Unit 
IRCCS Policlinico San Donato 
Piazza Malan, 1 
20097 San Donato Milanese, Milano 
ITALY 
Phone and FAX: 39-02-52774966 
Email: marco.guazzi@unimi.it 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
Abbreviations 
ACE- Angiotensin converting enzyme 
AV – Alveolar volume 
ATPase - Aadenosine triphosphatase  
CAV – Caveolin 
cGMP - cyclic guanosin monophosphate  
CO2 – Carbon dioxide 
DLco - Diffusing capacity for carbon monoxide  
DLNO - Diffusing capacity for nitric oxide 
EMT - epithelial-mesenchimal transition 
ET1 - endothelin-1   
GC - guanilate cyclase  
HF – Hearrt failure 
HFpEF – Heart failure-preserved ejection fraction 
HFrEF – Heart failure-reduced ejection fraction 
L-NMMA - NG-monomethyl-L-arginine 
LA- Left atrial   
LAP – Left atrial pressure 
LV – Left ventricular 
MCP-1 - Monocyte chemoattractant protein 1 
mPAP - mean pulmonary artery pressure  
NO – Nitric oxide  
O2 - Oxygen 
PH – Pulmonary hypertension 
PDE5 - phosphodiesterase 5  
Q – Pulmonary perfusion 
sGC - soluble guanylate cyclase  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
TGF-α1 - Transforming growth factor  
TNF-α - Tumor necrosis factor alpha 
V/Q – Ventilation/perfusion 
Abstract 
Cardiac dysfunction of both systolic and diastolic origin leads to increased left atrial pressure, lung capillary 
injury and increased resistance to gas transfer. Acutely, pressure-induced trauma disrupts the endothelial 
and alveolar anatomical configuration and definitively causes an impairment of cellular pathways involved 
in fluid-flux regulation and gas exchange efficiency, a process well identified as stress failure of the alveolar-
capillary membrane. In chronic heart failure (HF), additional stimuli other than pressure may trigger the 
true remodeling process of capillaries and small arteries characterized by endothelial dysfunction, 
proliferation of myofibroblasts, fibrosis and extracellular matrix deposition. In parallel there is a loss of 
alveolar gas diffusion properties due to the increased path from air to blood (thickening of extracellular 
matrix) and loss of fine molecular mechanism involved in fluid reabsorption and clearance. Deleterious 
changes in gas transfer not only reflect the underlying lung tissue damage but also portend independent 
prognostic information and may play a role in the pathogenesis of exercise limitations and ventilatory 
abnormalities observed in these patients. Few currently approved treatments for chronic HF have the 
potential to positively affect structural remodeling of the lung capillary network; angiotensin-converting 
enzyme inhibitors are one of the few currently established options. Recently, more attention has been paid 
to novel therapies specifically targeting the nitric oxide pathway as a suitable target to improve endothelial 
function and permeability as well as alveolar gas exchange properties.  
 
Key Words:  Endothelial dysfunction, lung capillaries, capillary unit. 
  
Introduction 
A typical feature of the failing left ventricle (LV) is the loss of its ability to relax and fill at normal pressures 
irrespective of the definition of heart  failure (HF) based on preserved or reduced ejection fraction 1. The 
pathophysiology of high end-diastolic pressures and its consequences on the lungs is complex and 
meaningful in clinical conditions involving both acute or chronic filling pressure elevation 2 . The most 
remarkable manifestation of an acute pressure challenge on lung capillaries is pulmonary edema, while 
pulmonary hypertension (PH) and right ventricular failure are the late consequences 3 .  
Despite the fact that these unfavorable conditions are highly prevalent and portend a negative outcome 4, 5 
the pathophysiology of left-sided heart disease associated with lung capillary injury is not completely 
understood and is infrequently considered as potential therapeutic target. 6 In this article we review the 
pathophysiological bases and clinical implications of lung capillary injury and its consequences in patients 
with left-sided heart disease. 
 
Lung Capillary Injury: Pathophysiological Bases  
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There is strong preclinical evidence that lung microcirculation impairment warrants attention as a 
determinant of unfavorable clinical outcome 7. When lung capillaries are exposed to an excessive 
hydrostatic pressure a stress failure phenomenon occurs, initially described by West and co-workers in a 
series of experimental preparations in different animal models 8. Stress failure challenges the anatomical 
integrity of the alveolar-capillary unit, alters endothelial permeability, fluid filtration and reabsorption and 
definitively leads to gas exchange impairment. Interstitial edema or alveolar flooding are the most 
impressive consequences of stress failure 8. Alternatively, when left atrial (LA) pressure elevation is less 
striking and is long-lasting, a true remodeling of capillaries and small arteries takes place. A cascade of 
hormonal and cytotoxic activation is involved in the remodeling process that unequivocally leads to 
abnormalities in gas exchange (Figure 1) 9. 
Tsukimoto et al. 10 studied the sequential disruption of the capillary endothelial and alveolar epithelial 
layers during a stepwise increase in hydrostatic pressure, reproducing the transition from interstitial 
leakage of protein (low permeability stage) to alveolar lumen leakage of protein and erythrocytes (high-
permeability stage of pulmonary edema). A number of animal studies that have focused on the biological 
features of alveolar stress failure have shown that mechanisms other than mechanical injury may 
contribute to capillary stress 11, 12. Induction of volume overload through 0.5 ml/min–1/kg–1 saline solution 
infusion for 180 min in the rabbit pulmonary artery was associated with a 44% portion of fluid accumulating 
in the interstitial space, ultrastructural changes, and impairment of gas transfer. 11 Development of 
hydraulic edema leads to activation of metalloproteinases, which degrades matrix proteo glycanstherevy 
altering the composition of the plasma membrane and contributing to increased endothelial membrane 
fluidity. The weakened tensile strength of the membrane potentiates endothelial stress failure 12. These 
findings might explain the acute rise in pulmonary hydrostatic pressure and pulmonary edema seen in 
humans, even if the pathophysiological correlates of alveolar–capillary stress failure in patients with cardiac 
disease have not been extensively investigated. In a study of 53 patients with acute cardiogenic pulmonary 
edema, injury of the alveolar–capillary barrier was associated with increased levels of plasma pulmonary 
surfactant associated proteins A and B and tumor necrosis factor (TNF)- α 13.  Persistence of elevated levels 
of TNF-α after pulmonary edema resolution may reflect pulmonary inflammation and explains why fluid 
accumulation can persist despite resolution of hydrostatic stress failure. 
When pressure injury is sustained a true remodeling process takes place that might not be reversible. 
Several experimental models of PH due to cardiac dysfunction have brought important insights into this 
area. In a descending coronary artery ligation post MI model, abnormalities in the lung microcirculation 
consisted of increased oxidative stress and diffuse inflammation 14 . 
Pacing-induced cardiomyopathy has been shown to produce alveolar–capillary membrane thickening as a 
result of excessive deposition of type IV collagen (the main component of the membrane lamina densa) 15. 
Similar findings were reported in a guinea pig model where an increased lamina was not accompanied by 
an increased lung water content 16, suggesting that  chronic proliferation rather than fluid accumulation 
predominates. In a mouse model of PH-HF-preserved ejection fraction (HFpEF) with LV hypertrophy, the LA 
pressure rise induced by aortic banding promoted impressive arteriolar remodeling, increased vascular 
oxidative stress, leucocyte infiltration and lung fibrosis after 4 weeks 17. In addition, lung weight changes 
were due to tissue and vascular changes rather than extravascular lung water 17. These features are 
reminiscent of the extracellular matrix thickening reported in patients with mitral stenosis and pulmonary 
venous pressure elevation 18, 19 in whom it accounts for the structural changes observed and might be 
viewed a safety mechanism against excessive fluid leakage from the capillaries. An increase in collagen 
content not observed in pre-capillary PH but typical of post-capillary PH is mediated by proliferation of 
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myofibroblasts termed “interstitial contractile cells (MYFs) 20. Growth factors that can trigger proliferation 
are classical local growth factors, such as angiotensin II, endothelin 1 (ET-1), TNF-α and especially 
transforming growth factor (TGF)-α1 which has been shown to be the major inducer of epithelial-
mesenchimal transition (EMT) in the fibrotic lung 21. The caveolin family of proteins (Cav-1, Cav-2, Cav-3), 
which are the main structural component of caveolar membranes surrounding the vescicular invaginations 
arising from plasma membranes, is seemingly involved in the remodelling process through hyperactivation 
of the Janus Kinase/signal transducer and activation of the transcription (JAK/STAT) signaling cascade 22. In 
mice knockout for Cav-2 there is a significant thickening of the alveolar septa and in the post- myocardial 
infarction (MI) model, Cav-1 and Cav-2 expression is reduced to undetectable levels 23. 
Recently, Park et al. 7 found that lung microvascular endothelial cells exposed to cyclic mechanical strain in 
vitro released proinflammatory and profibrotic mediators identifying a specific putative role for the 
monocyte chemoattractant protein 1 (MCP-1).   
The increase in lung interstitial connective tissue associated with chronic capillary hydrostatic overload 
results in increased extravascular fluid storage owing to increased production of an extracellular matrix 
component (mainly glycosaminoglycans) that has the potential to absorb and accommodate fluid in the 
interstitium. At least in cases of a subcritical rise in persistent LA pressure, this compensatory mechanism 
could prove beneficial by constraining fluid in the perivascular space without limiting gas diffusion 24. 
Alveolar hypoxia is another potential mediator that may substantially affect the composition of the 
extracellular matrix by increasing the expression of genes that encode extracellular matrix proteins 25. 
These structural modifications generally increase the impedance to gas transfer 26. In patients with HF, 
assessment of lung diffusion capacity by measuring the alveolar membrane conductance component 
enables quantification of the anatomical and functional integrity of the alveolar–capillary unit, which 
provides prognostic insights 27. Transition from stress failure to remodeling is a key step in the development 
of PH, and the true reversibility of this process is unknown.  
Endothelial Dysfunction- Once arteriolar remodeling has developed, the endothelium plays an integral role 
in mediating the functional alterations of the pulmonary vasculature 28. In the pulmonary circulation, the 
endothelium-mediated local control of vasomotility is primarily based on a balanced release of nitric oxide 
(NO) and ET-1 with the evidence suggesting that raised pulmonary pressure owing to left-sided heart 
disease is critically sensitive to an imbalance of these two opposing systems 29, 30.  
Studies performed in rats with PH and documented capillary remodeling have provided insights into the 
role endothelial NO-mediated dysfunction attributable to impaired Ca2+(i) endothelial homeostasis, as 
reflected by the lack of Ca2+ (i) oscillations and attenuation of the response to mechanical stress or 
chemical stress with histamine, acetylcholine or thapsigargin (FIGURE 2) 31. 
Studies with blockade of NO synthesis have provided evidence that endothelium-derived NO is a basic 
determinant of baseline pulmonary vascular tone, and a mediator of the dilating response to endothelium 
activation 32. In normals, systemic infusion of NG-monomethyl-L-arginine (L-NMMA), an analog of L-arginine 
that inhibits NO synthase, raises pulmonary artery pressure, enhances hypoxia-induced pulmonary 
vasoconstriction, 33 and inhibits the lung diffusion of carbon monoxide by lowering alveolar–capillary 
membrane conductance 34.  In patients with HF, infusion of L-NMMA in the pulmonary circuit causes a 
dose-dependent vasoconstriction, which is partially attenuated by acetylcholine 28. Human and animal 
studies suggest that NO-mediated pulmonary vasodilatation is impaired in left-sided heart disease. Porter 
et al. 35assessed pulmonary artery diameter with intravascular ultrasonography and reported vessel 
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dilatation when acetylcholine was infused in patients with LV dysfunction and normal pulmonary artery 
pressure, but dilatation was refractory when the baseline pressure was elevated. Data that supports 
attenuation or loss of NO-dependent vasodilatation as a basic contributor to pressure elevation have also 
been provided by recording pulmonary blood flow velocity during intrapulmonary infusion of L-NMMA 29. In 
healthy individuals and in patients with LV dysfunction with normal pulmonary vascular resistance, L-
NMMA elicited a conspicuous vasoconstrictor response. This effect was attenuated when L-NMMA was 
infused in patients with HF and PH. Notably, vasoconstriction was similar in the three groups in response to 
phenylephrine. 
Molecular Abnormalities in Alveolar Fluid Clearance-Fluid clearance from the alveoli to the capillaries is a 
process of vital importance. Na+ transport across the alveolar epithelium helps to reabsorb fetal fluid 36, 
ensuring a proper thinness of the adult alveolar fluid, the so-called film, and keeping alveolar space free of 
fluid, especially in pathologic states when alveolar permeability 37 to plasma proteins has been increased. 
The alveolar type II cell transport of Na+ (Figure 3) provides the major driving force for water removal from 
the alveolar space. After uptake, Na+ is pumped actively into the lung interstitium by Na+-K+ adenosine 
triphosphatase (ATPase). For an optimal gas exchange, the fine mechanisms that control alveolar Na+ and 
water metabolism are basically involved. Although disorders in lung diffusion in cardiac patients generally 
have been referred to as alterations of the endothelial and alveolar epithelial cells 38, experimental 
observations are also consistent with an involvement of alveolar water metabolism.  
Interestingly, in rats overexpressing, by adenovirus gene transfer, the Na+-K+ ATPase β1-subunit, there is an 
increase in liquid fluid clearance. In the same model, Na+ transport and alveolar fluid clearance in the 
presence of elevated left atrial pressure (LAP) was not different from that in rats studied at normal LAP 37. 
Hypoxia, another common consequence of chronic HF, is also capable of inhibiting alveolar Na+-K+ ATPase 
function and transalveolar fluid transport 39. These findings support the intriguing hypothesis that impaired 
Na+-K+ ATPase gene expression occurs during acute lung injury, and provide evidence that the result of a 
pressure and/or a volume overload on the lung circulation is an increase in capillary permeability to water 
and ions and disruption of local mechanisms for gas exchange.  
 
Detection of Lung Capillary Injury in Clinical Practice: Relevance of Gas Diffusion Abnormalities  
At variance with the systemic circulation, studies directly measuring endothelial function in the lung are 
limited to the invasive approach or to a simple, and in part questionable, correlation with a systemic 
endothelial flow-mediated response 40. Nonetheless, there is a strong rationale for taking the gas diffusing 
properties across the alveoli as an indirect indicator of endothelial permeability and therefore endothelial 
activity 26 . 
Measurement of lung diffusing capacity for carbon monoxide (DLco) or nitric oxide (DLNO) is generally used 
in clinical practice to evaluate the effectiveness of diffusive oxygen (O2) transport 41 . As originally 
suggested by Roughton and Forster 42, for a given alveolar volume and hemoglobin concentration, gas 
diffusion depends on two resistances arranged in series according to the following equation: 
 
1/DLCO= 1/Dm+ 1/ ɵCO x Vc 
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Where Dm is the alveolar-capillary membrane conductance, ɵCO is the rate of CO uptake by the whole 
blood in combination with hemoglobin measured in vitro and Vc is the capillary blood volume. Changes in 
Dm track structural alterations of the alveolar-capillary barrier, providing a sensitive noninvasive indication 
of microvascular integrity in health and disease. Vc is related to pulmonary capillary wedge pressure. In 
stable HF patients, Vc tends to increase in order to compensate for low Dm patients and this correlates 
with unfavorable hemodynamics and increased pulmonary vascular resistance 43. Reduction in the Dm 
component rather than changes in Vc accounted for observed gas diffusing abnormalities. Several reports 
43-4843-48 have confirmed and expanded these findings and in studies in which alveolar volume (AV) has 
been measured, abnormalities in DLco persisted even after AV normalization.  Patients with HF and 
diabetes comorbidity exhibit a more severe Dm impairment compared to patients with similar 
hemodynamic dysfunction without diabetes 48. 
Pathophysiologic Correlates. Studies investigating the pathophysiologic role of a reduced Dm in HF 
patients have addressed the question as to whether Dm changes are fixed or there is also a variable 
component related to interstitial edema and loss of fluid permeability. According to the basic experimental 
evidence that pulmonary interstitial fluid accumulation is secondary to a dysregulation of Na+ handling, 
changes in Dm following saline infusion have been investigated in patients with chronic HF of varying 
severity. In a study performed in post-MI patients with normal LV systolic function, an infusion of ~800 mL 
of saline reduced Dm by 13% 49. In patients with mild to severe HF, a 150 ml infusion of saline produced a 
significant Dm reduction equivalent to 750 ml saline, whereas a 750 mL infusion of isotonic glucose solution 
did not decrease DLco and Dm 50. None of these infusions caused changes in right atrial or pulmonary 
wedge pressures. These findings support the idea that part of Dm abnormalities are fluid-dependent and 
that Na+ infusion may be, even in a small amount, a challenge for cellular pathways involved in alveolar 
fluid clearance and capillary fluid reabsorption.  
Pulmonary abnormalities, and specifically those related to gas diffusion capacity, can explain part of the 
symptoms and functional limitations encountered in HF. Dm at rest and relative changes on exertion 
correlate with O2 uptake at peak exercise 51. The correlation, however, is even greater between Dm and 
the excessive ventilatory requirement to carbon dioxide (CO2) output, which is typical in these patients 52. 
The putative role of lung diffusion abnormalities in the pathophysiology of exercise limitation in HF has not 
been definitively appreciated because of the lack of significant O2 desaturation during exercise. In HF 
patients, however, despite the fact that pulmonary perfusion (Q) may be significantly reduced, the ability to 
appropriately recruit Dm for a given Q preserves the Dm/Q ratio and prevents O2 from significant drops 33. 
There is, however, documentation that development of subclinical pulmonary edema during exercise is a 
common finding in HF patients as suggested by a significant and persistent Dm and Dm/Vc reduction during 
the recovery phase of exercise 53. This may result in an increased sensation of dyspnea by activation of J 
receptor afferents, and there is a suggestion that the DM/Q ratio decreases and significant hypoxemia on 
exercise develops in some post-transplant patients. This is explained by the fact that pulmonary lung 
perfusion is reversed to normal in the presence of fixed ultrastructural membrane changes leading to 
exercise ventilation/perfusion (V/Q) mismatching. 
Therapeutic Perspectives 
In contrast with the increasing evidence of a pathophysiologic role, the opportunity to consider lung 
capillary function and alveolar fluid reabsorption as therapeutic targets are still underestimated 54. The 
importance of considering altered gas exchange as a target of treatment is underscored by the 
demonstration that despite major airway abnormalities, cardiac patients may improve with tailored 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
therapy; DLco remains low up to several years after heart transplantation and a relationship has been 
demonstrated between the time course of the disease and impedance to gas exchange 55. These findings 
are confirmatory of a progressive lung capillary remodeling process and suggest that a reduction in DLco 
reflects, at least in part, fixed structural changes. Consistently, in a prospective survival study where Dm 
and Vc were investigated, Dm was the only independent pulmonary predictor of worse prognosis in HF 
patients 56. 
Despite the lack of evidence of complete DLco and Dm normalization with treatment, a favorable 
modulatory activity on these variables by angiotensin converting enzyme (ACE)-inhibitors has been 
repeatedly reported 57. This effect appears promptly after drug administration, which persists over time 
and is unrelated to a lowering of pulmonary pressure. These mechanisms seem also to be involved in the 
overall benefits on survival produced by this class of drugs 56. Factors that reasonably may underlie the 
improvement in gas exchange with ACE-inhibitors include a modulation in extracellular matrix synthesis 
and collagen turnover, or an improvement in endothelial permeability and increased alveolar epithelial 
reabsorption of Na+ and fluid 58. Interestingly, an association has been found between DLco and ACE 
genotype polymorphism 47 , implying that higher ACE-inhibitors doses are very likely required for treating 
lung abnormalities of HF patients with ACE DD-genotype. Beta-blockers do not provide a similar reverse 
remodeling of the alveolar pneumocytes such as that occurring in the biological properties of 
cardiomyocites. A 6 month follow-up with carvedilol did not promote any improvement in DLco or Dm 59. 
The concern that antiarrhythmic treatment with amiodarone may exert untoward effects on lung diffusion 
may very likely be excluded by the demonstration in a relatively large population of HF patients that no 
DLco changes occurred after 1 year of amiodarone treatment 60. Since DLco may not adequately reflect 
abnormalities intrinsic to the alveolar epithelial and capillary layer, this question awaits further and more 
detailed studies. 
NO Pathway Overexpression. Since NO release by the pulmonary and venous endothelium is crucial for 
normal lung physiology, i.e. vascular permeability and molecular O2 transfer from the alveolus to its uptake 
by hemoglobin 33, its modulation/overexpression is seen as a meaningful target. In this regard, the most 
recent attention has been toward targeting the NO pathway at different downstream levels through 
overexpression of the cyclic guanosin monophosphate (cGMP) by two mainstay compounds, the 
phosphodiesterase 5 (PDE5) inhibitors and guanilate cyclase (GC) activators/stimulators. PDE-5 is the 
predominant isoenzyme that metabolizes cGMP, the second messenger of NO, which is highly generated in 
the smooth muscle cells of pulmonary arteries and veins. PDE-5 activity is increased in various experimental 
models of PH 61. In remarkable experiments by Yin et al, sildenafil given to a rat model of PH secondary to 
massive left ventricular hypertrophy was capable of reversing endothelial dysfunction and alveolar capillary 
remodeling, including capillary and small artery thickness that reversed their structural changes to normal 
after active drug therapy 62. 
In humans, inhibition of PDE-5 with sildenafil restores a normal cGMP transpulmonary gradient (increased 
arteriolar and capillary release) in patients with HF and high pulmonary vascular resistance 63. 
Evidence of the role of PDE5 inhibition on the pulmonary vasculature is increasing. Findings by our group 64 
suggest a long-term (1 year) sustained role for sildenafil in reducing pulmonary pressures and especially 
improving gas exchange (DLCO, Dm and Dm/VA) in a subset of patients with moderate to severe PH and 
HFpEF. In the placebo arm, there was a progressive increase in mean pulmonary artery pressure (mPAP). 
The associated rise of pulmonary arteriolar resistance with stable pulmonary arterial wedge pressure 
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suggests that changes in mPAP in these patients is due to evolution of the vascular disease rather than LV 
diastolic dysfunction.   
Recently, the introduction of additional compounds that target the downstream intracellular NO pathway 
by activation/stimulation of soluble guanylate cyclase (sGC) has offered another opportunity to overexpress 
cGMP signaling. Specifically, two trials 64, 65 have tested the acute effects of riociguat, a first in class 
compound that shows a dual mode of action: it sensitizes sGC to endogenous NO and directly stimulates 
sGC independently of NO.  
Both the LEPTH [patients with HF-reduced ejection fraction (HFrEF)] 65 and the DILATE (patients with HFpEF) 
66 trials have investigated hemodynamic effects, showing a good safety and tolerability profile, even with 
riociguat at different doses. However, no data has thus far been reported on endothelial function and gas 
exchange.  
Finally, there is the interesting perspective that interventions aimed at improving systemic endothelial 
function, such as aerobic exercise training, may also favorably impact gas exchange and pulmonary capillary 
properties. In a stable HF cohort, exercise training has been shown to improve gas diffusion through a 
combined effect on Dm and Vc and the normalization of alveolar volume. This suggests that repeated 
episodes of increased blood flow (i.e., shear stress) with exercise or metabolic effects of training may be 
the basis for a chronic stimulus for the release of endothelial paracrine agents, such as NO, that control 
vascular tone and permeability. These effects may not be confined to the exercising limbs but would be 
imposed throughout the vasculature, including the lungs 67. Information is still limited but represents a 
promising area for further investigation. 
 
 
Conclusions 
Development of cardiac dysfunction exposes the lung microcirculation to a pressure and/or volume 
overload; functional, physiologic and anatomical consequences have been outlined in different animal 
models and experimental conditions. Acutely, mechanical injury to the capillaries leads to the so-called 
stress failure, a process that causes endothelial and alveolar cell breakdown and impairs cellular pathways 
involved in control of vascular tone, fluid permeability and reabsorption. When the lung microcirculation is 
chronically challenged a typical remodeling process takes place characterized by fibroblast proliferation, 
fixed structural membrane alterations (i.e., extracellular matrix collagen proliferation) and re-expression of 
fetal genes. Remodeling leads to a sustained reduction in gas diffusion that does not appear to be totally 
reversible, as evidenced by the fact that abnormalities in alveolar gas diffusion persist for several years 
following heart transplantation.  Some therapeutic approaches that favorably impact the natural course of 
cardiac remodeling, such as ACE-inhibitors, exert a positive effect on alveolar properties and gas exchange. 
Therapies aimed at increasing lung capillary NO availability, such as exercise training, seem to be a 
promising opportunity for reversing capillary dysfunction and diminished alveolar membrane diffusive 
properties encountered in patients with HF. 
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Legend For Figures 
 
Figure 1  Elevation in left atrial pressure and proposed sequence of events that lead to capillary stress failure 
and remodelling of the capillaries and alveolar surface .  
 
An abnormal increase in left atrial pressure leads to alveolar stress failure, a process that disrupts the 
anatomical and functional properties of the capillaries (loss in permeability and fluid leakage) and alveoli 
unit (loss of absorption) but is reversible. In chronic PH, a superimposition of additional factors other than 
mechanical stress, such as neurohumoral, cytotoxic, hypoxic, and genetic factors, injure lung capillaries and 
alveolar spaces further, which triggers a remodeling process that ultimately result in some degree of 
protection against edema formation but impairment in gas exchange physiology. Abbreviations: ET1, 
endothelin-1; PH, pulmonary hypertension; TNF-α, tumor necrosis factor-α, TGF-β= transforming growth 
factor β; Cav-1=caveolin 1, Cav-2= caveolin 2 (adapted from Guazzi M et al Nature Review Cardiol 2010) 9. 
 
Figure 2. Schematic presentation of the molecular and cellular pathways involved in alveolar fluid clearance. 
Na+ enters the apical membrane of alveolar type II cells mainly through the amiloride-sensitive epithelial 
Na+ channels, and is then transported across the basolateral membrane in to the interstitium through the 
ouabain-inhibitable Na+/K+ ATPase pump. On the apical surface of type II cells there is also a glucose 
cotransport system for Na+.  The passive Na+ transport generates an osmotic gradient that induces removal 
of excessive intralveolar fluid. In several clinical conditions such as HF, a defect of this mechanism 
predisposes patients to pulmonary edema regardless of Starling forces and lymphatic drainage (adapted 
from Guazzi M J Card Fail 2008) 17. 
 
Figure 3. Experimental insights on the molecular mechanisms that lead to endothelial dysfunction once a 
capillary remodelling develops secondary to left sided PH.  
9 weeks of aortic banding determined a lack of endothelial NO release during acetylcholine stimuli assessed 
in vivo with luminescence technique. This was accompanied by a lack of physiological oscillations in Ca2+ 
endothelial handling working as a trigger for the occurrence of important cytoskeleton dysorganization 
(adapted from ref. Yin J Circ Heart Fail 2011;4:198)61 
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